Emerging role of the urotensin II system in cardiovascular disease

HeartDrug

Volumn 3, Issue 3, 2003, Pages 153-158

  Krum, Henry ^a   Kompa, Andrew ^a   Hannan, Ross ^b   Thomas, Walter ^b  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Heart failure; Myocardial infarction; Urotensin II; Vasoconstrictor peptide

Indexed keywords

INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II ANTAGONIST;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; EXTRACELLULAR MATRIX; HEART FAILURE; HEMODYNAMICS; HUMAN; MUSCLE CELL; MUSCLE HYPERTROPHY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VASCULARIZATION; VASOCONSTRICTION;

EID: 0345689376     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072742     Document Type: Review

References (28)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Douglas SA, et al: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286.
2. Davenport AP, Maguire JJ: Urotensin II: Fish neuropeptide catches orphan receptor. Trends Pharmacol Sci 2000;21:80-82.
3. Douglas SA, Ohlstein EH: Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000;10:229-237.
4. Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, Kikuchi K, Shintani Y, Kurokawa T, Onda H, Nishimura O, Fujino M: Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 1999;265:123-129.
5. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O: Role of urotensin II in patients on dialysis. Lancet 2001;358:810-811.
6. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN: Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000;131:1262-1274.
7. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Polland K: Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000;130:201-204.
8. Gray GA, Jones MR, Sharif I: Human urotensin II increases coronary perfusion pressure in the isolated rat heart: Potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 2001;69:175-180.
9. Bottrill FE, Douglas SA, Hiley CR, White R: Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000;130:1865-1870.
10. Camarda V, Rizzi A, Calo G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D: Effects of human urotensin II in isolated vessels of various species: Comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 2002;365:141-149.
11. Gardiner SM, March JE, Kemp PA, Davenport AP, Bennett T: Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001;132:1625-1629.
12. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, McMurray J: Effects of urotensin II in human arteries and veins of varying caliber. Circulation 2001;103:1378-1381.
13. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR: Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol 2001;280:H925-H928.
14. Bohm F, Pernow J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002;135:25-27.
15. Wilkinson IB, Affolter JT, de Haas SL, Pellegrini MP, Boyd J, Winter MJ, Balment RJ, Webb DJ: High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002;53:341-347.
16. Watanabe T, Pakala R, Katagiri T, Benedict CR: Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 2001;104:16-18
17. Sauzeau V, Le Mellionnec E, Bertoglio J, Scal-bert E, Pacaud P, Loirand G: Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001;88:1102-1104.
18. Kuc RE, Maguire JJ, Davenport AP: Urotensin-II is a potent constrictor of human atherosclerotic coronary arteries with immunoreactive peptide localized to the atherosclerotic plaque. Br J Pharmacol 2001;134:75.
19. Russell FD, Molenaar P, O'Brien DM: Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 2001;132:5-9.
20. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, Kelly DJ, Gilbert RE, Krum H: Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003;93:246-253.
21. Douglas SA, Tayara L, Ohlstein E, Halawa N, Giaid A: Congestive heart failure and myocardial expression of urotensin II. Lancet 2002;359:1990-1997.
22. Dschietzig T, Bartsch C, Pregla R, Zurbrugg HR, Armbruster FP, Richter C, Laule M, Romeyke E, Neubert C, Voelter W, Baumann G, Stangl K: Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 2002;110:33-38.
23. Kruger S, Graf J, Janssens U, Stickel T, Kunz D, Hanrath P: Human urotensin II and big endothelin in patients with chronic heart failure. XXIII Congress of the European Society of Cardiology 2001 (abstract 538). Eur Heart J 2002;23(abstr suppl).
24. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG: Plasma urotensin II in heart failure. Lancet 2002;360:545-546.
25. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE: Plasma urotensin in human systolic heart failure. Circulation 2002;106:2877-2880.
26. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O: Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003;104:1-5.
27. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, Douglas SA: Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val- Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 2002;137:449-458.
28. Kalra PR, Moon JC, Coats AJ: Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002;85:195-197.